Santhera Pharmaceuticals Holding AG Statistics

Total Valuation

Santhera Pharmaceuticals Holding AG has a market cap or net worth of GBP 186.09 million. The enterprise value is 194.93 million.

Market Cap	186.09M
Enterprise Value	194.93M

Important Dates

The next estimated earnings date is Wednesday, May 28, 2025.

Earnings Date	May 28, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+24.61%
Shares Change (QoQ)	+6.07%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	9.46M

Valuation Ratios

The trailing PE ratio is 3.36.

PE Ratio	3.36
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 3.78, with an EV/FCF ratio of 4.69.

EV / Earnings	3.52
EV / Sales	1.92
EV / EBITDA	3.78
EV / EBIT	4.06
EV / FCF	4.69

Financial Position

The company has a current ratio of 0.63, with a Debt / Equity ratio of 0.55.

Current Ratio	0.63
Quick Ratio	0.51
Debt / Equity	0.55
Debt / EBITDA	0.46
Debt / FCF	0.56
Interest Coverage	3.10

Financial Efficiency

Return on equity (ROE) is 2,374.13% and return on invested capital (ROIC) is 91.78%.

Return on Equity (ROE)	2,374.13%
Return on Assets (ROA)	39.20%
Return on Capital (ROIC)	91.78%
Revenue Per Employee	2.22M
Profits Per Employee	1.23M
Employee Count	45
Asset Turnover	1.33
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +63.92% in the last 52 weeks. The beta is 0.13, so Santhera Pharmaceuticals Holding AG's price volatility has been lower than the market average.

Beta (5Y)	0.13
52-Week Price Change	+63.92%
50-Day Moving Average	10.48
200-Day Moving Average	9.70
Relative Strength Index (RSI)	76.33
Average Volume (20 Days)	6,757

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Santhera Pharmaceuticals Holding AG had revenue of GBP 100.02 million and earned 55.35 million in profits. Earnings per share was 5.02.

Revenue	100.02M
Gross Profit	94.28M
Operating Income	47.31M
Pretax Income	55.61M
Net Income	55.35M
EBITDA	50.43M
EBIT	47.31M
Earnings Per Share (EPS)	5.02

Full Income Statement

Balance Sheet

The company has 14.52 million in cash and 23.22 million in debt, giving a net cash position of -8.70 million.

Cash & Cash Equivalents	14.52M
Total Debt	23.22M
Net Cash	-8.70M
Net Cash Per Share	n/a
Equity (Book Value)	42.32M
Book Value Per Share	3.62
Working Capital	-17.09M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 41.69 million and capital expenditures -142,651, giving a free cash flow of 41.55 million.

Operating Cash Flow	41.69M
Capital Expenditures	-142,651
Free Cash Flow	41.55M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 94.26%, with operating and profit margins of 47.30% and 55.34%.

Gross Margin	94.26%
Operating Margin	47.30%
Pretax Margin	55.60%
Profit Margin	55.34%
EBITDA Margin	50.42%
EBIT Margin	47.30%
FCF Margin	41.54%

Dividends & Yields

Santhera Pharmaceuticals Holding AG does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-24.61%
Shareholder Yield	-24.61%
Earnings Yield	29.74%
FCF Yield	22.33%

Stock Splits

The last stock split was on July 3, 2023. It was a reverse split with a ratio of 0.1.

Last Split Date	Jul 3, 2023
Split Type	Reverse
Split Ratio	0.1

Scores

Santhera Pharmaceuticals Holding AG has an Altman Z-Score of -4.18. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-4.18
Piotroski F-Score	n/a